Boiler Room: The Official Stock Market Discussion

[Doomsday]

Cathie and Elon bout to make me rich twice.

 

[FabTrey]

NNOX


maybe i should swing this hoe. it was over $60 just few days ago

 

[El Bombi]

I'm watching the Marathon dip.

 

[ExodusNirvana]

Missed out on ABIO at the open

Gonna dip my toe in now...just a lil bit

 

[K-Deini]

Missed out on ABIO at the open

Gonna dip my toe in now...just a lil bit

Welcome to the club

 

[Kyle C. Barker]

Interesting. A lot of people, including myself, don’t think slack is viable as a stand-alone product. They need to merge with someone like zoom or get acquired, they’re a strong player but too many other options out there including MSFT who has made it a goal to kill them

I agree and I'm actually a fan of slack but Microsoft teams pretty much made short work of slack since the corporate heads liked how it connects with thier Microsoft products.


For what it's worth I'd rather use slack than zoom for work

 

[K-Deini]

Gains are back

 

[old pig]

dumping them immediately or around battery day

I’m gonna sell the day before to avoid being greedy...hoping I don’t leave too much on the table cuz battery day gonna be crazy...RH might “shutdown” again lmao

 

[Serious]

Lowes has a black ceo

 

[FabTrey]

WKS is already $25

I blew my chance at $5-7.

this couldve been my next INO.

 

[No1]

What is ABIO and why are some of you so bullish on it?

 

[Serious]

Palihapitiya finds next '10x idea' with $4.8 billion SPAC deal for real estate start-up Opendoor

 

[NatiboyB]

Palihapitiya finds next '10x idea' with $4.8 billion SPAC deal for real estate start-up Opendoor

why didnt I keep SPAC

 

[old pig]

why didnt I keep SPAC

IPOB I think

Opendoor, a Leading Digital Platform for Residential Real Estate, Announces Plans to Become Publicly-traded via Merger with Social Capital Hedosophia

 

[FabTrey]

What is ABIO and why are some of you so bullish on it?

its a dirt cheap covid set up got beat down in august.

While Arca Biopoharma hasn’t issued any news as of late, there’s good reason to be excited about the stock. The company is currently working on a treatment known as AB201 as a potential treatment option for COVID-19.

It is expected that some time before the end of the month, the company will submit its Investigational New Drug Application to the FDA in order to move forward with a Phase IIb clinical trial.

If all goes well, the ABIO Phase IIb trial will start as early as next quarter. That’s exciting.


The fact of the matter is that while vaccines seem to be on the way, COVID-19 is likely to be a long-term issue. After all, this isn’t the only coronavirus that human kind has seen. In fact, coronavirus strains are the reason we get the common cold.

Importantly, the common cold has shown us what to expect. Even if vaccines are effective, immune effects from the vaccine, or vaccines, will not last forever. Not to mention, there’s a large population of consumers that refuse to take vaccinations.

As a result, there’s good reason to expect that COVID-19 is going to be here fore the long-haul. With a condition like this being around, there will need to be effective treatment options. Of course, if ABIO proves that its AB201 treatment is effective, it could take a large piece of this growing market moving forward.